EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
EDEMA2 is an open-label, Phase 2 dose-ranging study designed to assess the safety and
efficacy of repeated dosing of DX-88 (recombinant plasma kallikrein inhibitor) in Patients
with Hereditary Angioedema.